癌症耐药(英文)Pub Date : 2024-11-19eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.131
Mario Cioce, Mariamena Arbitrio, Nicoletta Polerà, Emanuela Altomare, Antonia Rizzuto, Carmela De Marco, Vito Michele Fazio, Giuseppe Viglietto, Maria Lucibello
{"title":"Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity.","authors":"Mario Cioce, Mariamena Arbitrio, Nicoletta Polerà, Emanuela Altomare, Antonia Rizzuto, Carmela De Marco, Vito Michele Fazio, Giuseppe Viglietto, Maria Lucibello","doi":"10.20517/cdr.2024.131","DOIUrl":"https://doi.org/10.20517/cdr.2024.131","url":null,"abstract":"<p><p>Resistance of cancer to therapy is the main challenge to its therapeutic management and is still an unsolved problem. Rearranged lipid metabolism is a strategy adopted by cancer cells to counteract adversity during their evolution toward aggressiveness and immune evasion. This relies on several mechanisms, ranging from altered metabolic pathways within cancer cells to evolved dynamic crosstalk between cancer cells and the tumor microenvironment (TME), with some cell populations at the forefront of metabolic reprogramming, thereby contributing to the resistance of the whole ecosystem during therapy. Unraveling these mechanisms may contribute to the development of more effective combinatorial therapy in resistant patients. This review highlights the alterations in lipid metabolism that contribute to cancer progression, with a focus on the potential clinical relevance of such findings for the management of therapy resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"45"},"PeriodicalIF":4.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells.","authors":"Feng Zeng, Jiaying Cao, Yan Chen, Jingqiong Tang, Qian He, Shan Liao, Lin Liang, Wentao Li, Siyi Liu, Gengqiu Luo, Yanhong Zhou","doi":"10.20517/cdr.2024.101","DOIUrl":"https://doi.org/10.20517/cdr.2024.101","url":null,"abstract":"<p><p><b>Aim:</b> Gastric cancer (GC) is one of the common malignant tumors, and most patients with advanced GC often develop chemotherapy resistance, resulting in poor chemotherapy efficacy. Therefore, it is crucial to clarify the specific mechanisms of their chemotherapy resistance. <b>Methods:</b> In this study, we analyzed the correlation between fos-related antigen-1 (Fra-1) and chemotherapy resistance in GC using bioinformatics, cell counting kit-8 (CCK8), and 5-ethynyl-2'-deoxyuridine (EDU) combined with flow cytometry; furthermore, we used energy metabolomics sequencing, combined with ChIP-qPCR technology, to elucidate the specific role of Fra-1 in chemotherapy resistance of GC cells and its related mechanisms. <b>Results:</b> We found that high Fra-1 expression was closely related to chemotherapeutic drugs in GC cells, as demonstrated by bioinformatics analysis combined with EDU and CCK8 experiments. Energy metabolomics combined with <i>in vitro</i> cellular experimental analysis revealed that the pentose phosphate pathway (PPP) was activated in GC cells with high Fra-1 expression, along with an increase in the synthesis of metabolites such as nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH), a decrease in the level of reactive oxygen species (ROS), and the inhibition of their ferroptosis. In addition, ChIP-qPCR experiments confirmed that Fra-1 binds to the promoter of glucose-6-phosphate dehydrogenase (G6PD), a key rate-limiting enzyme of the PPP, and transcriptionally regulates its expression, which in turn activates the PPP and promotes chemotherapy resistance in GC cells. <b>Conclusion:</b> Our research findings suggest that Fra-1 activates the PPP by upregulating G6PD transcriptional activity and inhibiting its ubiquitination level, inhibiting ferroptosis in GC cells and inducing chemoresistance. This provides an experimental basis for screening potential molecular targets for chemotherapy resistance in GC patients.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"44"},"PeriodicalIF":4.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role and clinical applications of exosomes in cancer drug resistance.","authors":"Wenxuan Pan, Qun Miao, Wenqian Yin, Xiaobo Li, Wencai Ye, Dongmei Zhang, Lijuan Deng, Junqiu Zhang, Minfeng Chen","doi":"10.20517/cdr.2024.97","DOIUrl":"https://doi.org/10.20517/cdr.2024.97","url":null,"abstract":"<p><p>Tumor-secreted exosomes are heterogeneous multi-signal messengers that support cancer growth and dissemination by mediating intercellular crosstalk and activating signaling pathways. Distinct from previous reviews, we focus intently on exosome-therapeutic resistance dynamics and summarize the new findings about the regulation of cancer treatment resistance by exosomes, shedding light on the complex processes via which these nanovesicles facilitate therapeutic refractoriness across various malignancies. Future research in exosome biology can potentially transform diagnostic paradigms and therapeutic interventions for cancer management. This review synthesizes recent insights into the exosome-driven regulation of cancer drug resistance, illuminates the sophisticated mechanisms by which these nanovesicles facilitate therapeutic refractoriness across various malignancies, and summarizes some strategies to overcome drug resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"43"},"PeriodicalIF":4.6,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-10-31eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.54
Anum Jalil, Melissa M Donate, Jane Mattei
{"title":"Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.","authors":"Anum Jalil, Melissa M Donate, Jane Mattei","doi":"10.20517/cdr.2024.54","DOIUrl":"https://doi.org/10.20517/cdr.2024.54","url":null,"abstract":"<p><p>Melanoma is the most aggressive form of skin cancer, characterized by a poor prognosis, and its incidence has risen rapidly over the past 30 years. Recent therapies, notably immunotherapy and targeted therapy, have significantly improved the outcome of patients with metastatic melanoma. Previously dismal five-year survival rates of below 5% have shifted to over 50% of patients surviving the five-year mark, marking a significant shift in the landscape of melanoma treatment and survival. Unfortunately, about 50% of patients either do not respond to therapy or experience early or late relapses following an initial response. The underlying mechanisms for primary and secondary resistance to targeted therapies or immunotherapy and relapse patterns remain not fully identified. However, several molecular pathways and genetic factors have been associated with melanoma resistance to these treatments. Understanding these mechanisms paves the way for creating novel treatments that can address resistance and ultimately enhance patient outcomes in melanoma. This review explores the mechanisms behind immunotherapy and targeted therapy resistance in melanoma patients. Additionally, it describes the treatment strategies to overcome resistance, which have improved patients' outcomes in clinical trials and practice.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"42"},"PeriodicalIF":4.6,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-10-25eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.123
Daolin Tang, Rui Kang
{"title":"NFE2L2 and ferroptosis resistance in cancer therapy.","authors":"Daolin Tang, Rui Kang","doi":"10.20517/cdr.2024.123","DOIUrl":"https://doi.org/10.20517/cdr.2024.123","url":null,"abstract":"<p><p>NFE2-like basic leucine zipper transcription factor 2 (NFE2L2, also known as NRF2), is a key transcription factor in the cellular defense against oxidative stress, playing a crucial role in cancer cell survival and resistance to therapies. This review outlines the current knowledge on the link between NFE2L2 and ferroptosis - a form of regulated cell death characterized by iron-dependent lipid peroxidation - within cancer cells. While NFE2L2 activation can protect normal cells from oxidative damage, its overexpression in cancer cells contributes to drug resistance by upregulating antioxidant defenses and inhibiting ferroptosis. We delve into the molecular pathways of ferroptosis, highlighting the involvement of NFE2L2 and its target genes, such as <i>NQO1</i>, <i>HMOX1</i>, <i>FTH1</i>, <i>FTL</i>, <i>HERC2</i>, <i>SLC40A1</i>, <i>ABCB6</i>, <i>FECH</i>, <i>PIR</i>, <i>MT1G</i>, <i>SLC7A11</i>, <i>GCL</i>, <i>GSS</i>, <i>GSR</i>, <i>GPX4</i>, <i>AIFM2</i>, <i>MGST1</i>, <i>ALDH1A1</i>, <i>ALDH3A1</i>, and <i>G6PD</i>, in ferroptosis resistance. Understanding the delicate balance between NFE2L2's protective and deleterious roles could pave the way for novel therapeutic strategies targeting NFE2L2 to enhance the efficacy of ferroptosis inducers in cancer therapy.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"41"},"PeriodicalIF":4.6,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-10-18eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.53
Aubrey L Miller, Patrick L Garcia, Rebecca B Vance, Eric O Heard, Eric J Brown, Karina J Yoon
{"title":"The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models.","authors":"Aubrey L Miller, Patrick L Garcia, Rebecca B Vance, Eric O Heard, Eric J Brown, Karina J Yoon","doi":"10.20517/cdr.2024.53","DOIUrl":"https://doi.org/10.20517/cdr.2024.53","url":null,"abstract":"<p><p><b>Aim:</b> Cell division cycle 25B (CDC25B) belongs to the CDC25 family of phosphatases that regulate cell cycle progression. CDC25B also contributes to tumor initiation and progression, but no connection between CDC25B levels and drug sensitivity in pancreatic cancer has been reported. Based on our finding that bromodomain and extraterminal domain (BET) inhibitors decrease levels of CDC25B, we aim to compare the sensitivity of models expressing contrasting levels of CDC25B to the BET inhibitor JQ1, in pancreatic cancer cell lines <i>in vitro</i> and in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC) <i>in vivo</i>. <b>Methods:</b> We compared the efficacy of the standard of care agent gemcitabine with the BET inhibitor JQ1, using alamarBlue assays to determine IC<sub>50</sub>s of three pancreatic cancer cell lines <i>in vitro</i>. We used immunohistochemistry (IHC) and immunoblot (IB) to detect CDC25B. We also compared the effect of each agent on the progression of PDX models of PDAC <i>in vivo</i> with contrasting levels of CDC25B. <b>Results:</b> Immunohistochemical data demonstrated that levels of CDC25B differed by ~2- to 5-fold in cell lines and PDX models used. <i>In vitro</i> data showed that the level of CDC25B paralleled sensitivity to JQ1. Similarly, <i>in vivo</i> data showed that tumors with high-level CDC25B were more sensitive to JQ1 than tumors with lower CDC25B. The combination of JQ1 + a pan CDC25 inhibitor was synergistic in gemcitabine-resistant Panc1.gemR cells that had relatively high levels of CDC25B expression compared to parent cells. <b>Conclusion:</b> The data suggest that CDC25B may be an independent indicator of sensitivity to BET inhibitors and that CDC25B may contribute to gemcitabine insensitivity in this tumor type.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"40"},"PeriodicalIF":4.6,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-10-15eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.67
Joanna Kefas, Michael Flynn
{"title":"Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.","authors":"Joanna Kefas, Michael Flynn","doi":"10.20517/cdr.2024.67","DOIUrl":"https://doi.org/10.20517/cdr.2024.67","url":null,"abstract":"<p><p>Ovarian cancer is a significant global health challenge, with cytoreductive surgery and platinum-based chemotherapy serving as established primary treatments. Unfortunately, most patients relapse and ultimately become platinum-resistant, at which point there are limited effective treatment options. Given the success of immunotherapy in inducing durable treatment responses in several other cancers, its potential in platinum-resistant ovarian cancer (PROC) is currently being investigated. However, in unselected advanced ovarian cancer populations, researchers have reported low response rates to immune checkpoint inhibition, and thus far, no validated biomarkers are predictive of response. Understanding the intricate interplay between platinum resistance, immune recognition, and the tumour microenvironment (TME) is crucial. In this review, we examine the research challenges encountered thus far, the biological rationale for immunotherapy, the underlying mechanisms of immune resistance, and new strategies to overcome resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"39"},"PeriodicalIF":4.6,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-09-27eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.81
Jingcun Shi, Ying Shen, Jianjun Zhang
{"title":"Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.","authors":"Jingcun Shi, Ying Shen, Jianjun Zhang","doi":"10.20517/cdr.2024.81","DOIUrl":"https://doi.org/10.20517/cdr.2024.81","url":null,"abstract":"<p><p>Studies of carcinogenic metabolism have shown that cancer cells have significant metabolic adaptability and that their metabolic dynamics undergo extensive reprogramming, which is a fundamental feature of cancer. The Warburg effect describes the preference of cancer cells for glycolysis over oxidative phosphorylation (OXPHOS), even under aerobic conditions. However, metabolic reprogramming in cancer cells involves not only glycolysis but also changes in lipid and amino acid metabolism. The mechanisms of these metabolic shifts are critical for the discovery of novel cancer therapeutic targets. Despite advances in the field of oncology, chemotherapy resistance, including multidrug resistance, remains a challenge. Research has revealed a correlation between metabolic reprogramming and anticancer drug resistance, but the underlying complex mechanisms are not fully understood. In addition, small extracellular vesicles (sEVs) may play a role in expanding metabolic reprogramming and promoting the development of drug resistance by mediating intercellular communication. The aim of this review is to assess the metabolic reprogramming processes that intersect with resistance to anticancer therapy, with particular attention given to the changes in glycolysis, lipid metabolism, and amino acid metabolism that accompany this phenomenon. In addition, the role of sEVs in disseminating metabolic reprogramming and promoting the development of drug-resistant phenotypes will be critically evaluated.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"38"},"PeriodicalIF":4.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
癌症耐药(英文)Pub Date : 2024-09-25eCollection Date: 2024-01-01DOI: 10.20517/cdr.2024.66
Kenneth K W To, Hang Zhang, William C Cho
{"title":"Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy.","authors":"Kenneth K W To, Hang Zhang, William C Cho","doi":"10.20517/cdr.2024.66","DOIUrl":"https://doi.org/10.20517/cdr.2024.66","url":null,"abstract":"<p><p>Competing endogenous RNAs (ceRNAs) are transcripts that possess highly similar microRNA response elements (MREs). microRNAs (miRNAs) are short, endogenous, single-stranded non-coding RNAs (ncRNAs) that can repress gene expression by binding to MREs on the 3' untranslated regions (UTRs) of the target mRNA transcripts to suppress gene expression by promoting mRNA degradation and/or inhibiting protein translation. mRNA transcripts, circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and transcribed pseudogenes could share similar MREs, and they can compete for the same pool of miRNAs. These ceRNAs may affect the level of one another by competing for their shared miRNAs. This interplay between different RNAs constitutes a ceRNA network, which regulates many important biological processes. Cancer drug resistance is a major factor leading to treatment failure in patients receiving chemotherapy. It can be acquired through genetic, epigenetic, and various tumor microenvironment mechanisms. The involvement of ceRNA crosstalk and its disruption in chemotherapy resistance is attracting attention in the cancer research community. This review presents an updated summary of the latest research on ceRNA dysregulation causing drug resistance across different cancer types and chemotherapeutic drug classes. Interestingly, accumulating evidence suggests that ceRNAs may be used as prognostic biomarkers to predict clinical response to cancer chemotherapy. Nevertheless, detailed experimental investigations of the putative ceRNA networks generated by computational algorithms are needed to support their translation for therapeutic and prognostic applications.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"37"},"PeriodicalIF":4.6,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions <i>in vitro</i>.","authors":"Shruti Vig, Payal Srivastava, Idrisa Rahman, Renee Jaranson, Anika Dasgupta, Robert Perttilä, Petteri Uusimaa, Huang-Chiao Huang","doi":"10.20517/cdr.2024.50","DOIUrl":"https://doi.org/10.20517/cdr.2024.50","url":null,"abstract":"<p><p><b>Aim:</b> ATP-binding cassette (ABC) transporters are proteins responsible for the efflux of drug molecules from cancer cells, reducing the efficacy of anti-cancer treatments. This study assesses the susceptibility of a panel of clinically used photosensitizers to be transported by ABC transporters <i>in vitro.</i> <b>Methods:</b> The involvement of P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated protein 1 (MRP1/ABCC1) in the transport of 7 clinically utilized photosensitizers [benzoporphyrin derivative (BPD), temoporfin, redaporfin, talaporfin sodium, rose bengal, methylene blue, and indocyanine green] were investigated using human breast cancer cell lines following well-established protocols. Briefly, parental MCF-7 cells and sublines that overexpress P-gp (MCF-7 TX400), ABCG2 (MCF-7 MX100), or MRP1 (MCF-7/VP) were treated with photosensitizers with and without ABC transporter inhibitors. Intracellular levels of photosensitizers were measured using extraction method and flow cytometry to determine whether the ABC transporters are associated with efflux or uptake of photosensitizers. <b>Results:</b> The ABCG2 inhibitor (fumitremorgin C) and P-gp inhibitor (valspodar) effectively blocked the transport mediated by ABCG2 and P-gp of rose bengal and BPD. Redaporfin showed increased accumulation in the presence of valspodar with flow cytometry. Interestingly, MCF-7/VP cells were found to have reduced intracellular accumulation of rose bengal, which was restored with MRP1 inhibitor (MK571). The cell viability assay showed photodynamic therapy (PDT) resistance with Redaporfin in P-gp-overexpressing cells, BPD in ABCG2- and P-gp-overexpressing cells, and with Rose bengal in ABCG2-, P-gp- and MRP1-overexpressing cells, respectively. However, no change in intracellular retention was observed for other photosensitizers. <b>Conclusion:</b> In summary, our study provided new knowledge that temoporfin, talaporfin sodium, methylene blue, and indocyanine green are not substrates of ABCG2, P-gp, or MRP1. Redaporfin is a substrate for P-gp. BPD is a known substrate of ABCG2 and P-gp. Rose bengal is a substrate of ABCG2, P-gp, and MRP1. The results presented here indicate ABC transporter substrate status as a possible cause for cellular resistance to photodynamic therapy with rose bengal, redaporfin, and BPD.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"35"},"PeriodicalIF":4.6,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}